KRYS
Krystal Biotech, Inc.
Set alert
- YTD
- +34.78%
- 1 year
- +75.74%
- Open
- 325.83
- Prev close
- 324.55
- Mkt cap
- 9.84B
- Vol
- 330.31K
- Avg vol
- 274.83K
- EPS
- 7.98
- P/E
- 41.64
- Div yield
- 0.00%
More statistics
- Low
- 319.95
- High
- 332.63
- Forward P/E
- 37.12
- Beta
- 0.50
- Short ratio
- 9.85
- Inst. own
- 102.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 337.56
- 200-d avg
- 308.33
- 1y target
- 395.44
Key statistics
- Market cap
- 9.84B
- Enterprise value
- 8.77B
- Trailing P/E
- 41.64
- Forward P/E
- 37.12
- PEG ratio
- 0.00
- Price / sales
- 22.33
- Price / book
- 7.24
- EPS (TTM)
- 7.98
- Beta
- 0.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 54.82%
- Revenue (TTM)
- 440.48M
- Revenue growth
- 24.10%
- Free cash flow
- 151.74M
- Total cash
- 845.63M
- Total debt
- 8.85M
- Return on equity
- 20.12%
- Shares outstanding
- 29.60M
- Short % of float
- 16.24%
- 50-day average
- 337.56
- 200-day average
- 308.33
Analyst view
Consensus: strong buy
- Target (low)
- 284.00
- Target (mean)
- 395.44
- Target (high)
- 474.00
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 1.92.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 1.79 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 1.70 | 1.79 | +0.09 | +5.29% |
| May 4, 2026 | Mar 31, 2026 | 1.45 | 1.83 | +0.38 | +26.21% |
| Feb 17, 2026 | Dec 31, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Nov 3, 2025 | Sep 30, 2025 | 1.12 | 2.66 | +1.54 | +137.50% |
| Aug 4, 2025 | Jun 30, 2025 | 1.08 | 1.29 | +0.21 | +19.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 14, 2026 | RBC Capital | init | — | Outperform |
| Aug 4, 2026 | Citigroup | main | Buy | Buy |
| Jul 14, 2026 | B of A Securities | main | Buy | Buy |
| Jun 18, 2026 | TD Cowen | main | Buy | Buy |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- krystalbio.com
News
- Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
- Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
- HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
- Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
- Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome
- $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
- Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
- Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target
- B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400
- Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Your note
Sign in to keep a note on KRYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANNEY DANIEL SPENCER | Director | Sale | Feb 26, 2026 | 0 |
| KRISHNAN KRISH S | Chief Executive Officer | Sale | Sep 3, 2026 | 1,565,250 |
| KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | Sep 3, 2026 | 1,493,160 |
| ROMANO KATHRYN | Officer | Sale | Mar 1, 2026 | 22,366 |
| ROSSI DINO A | Director | Stock Gift | Aug 13, 2026 | 50,000 |
| THOMAS JOHN CHARLES MICHAEL | General Counsel | Sale | Jun 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.93% | 4,418,197 | 1.47B | Jun 29, 2026 |
| Blackrock Inc. | 14.13% | 4,181,432 | 1.39B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 9.76% | 2,888,888 | 959.95M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.32% | 1,574,905 | 523.33M | Jun 29, 2026 |
| State Street Corporation | 4.56% | 1,351,158 | 448.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 1,240,567 | 412.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.09% | 1,802,622 | 598.99M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.21% | 948,897 | 315.31M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 889,548 | 295.59M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.76% | 816,132 | 271.19M | Aug 30, 2026 |
| SmallCap World Fund Inc | 2.54% | 752,244 | 249.96M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 675,066 | 224.32M | Sep 29, 2026 |